NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

Phase 1

Completed

Conditions: Adult Anaplastic Astrocytoma
Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: ixabepilone
Other: pharmacological study
Drug: Anticonvulsant

First Posted Date: 2003-01-27

Last Posted Date: 2017-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00045708

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Phase 2

Completed

Conditions: Advanced Malignant Mesothelioma
Epithelial Mesothelioma
Localized Malignant Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatous Mesothelioma

Interventions: Drug: gemcitabine hydrochloride
Drug: cisplatin
Biological: bevacizumab
Other: placebo
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 106

Registration Number: NCT00027703

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

BMS-214662 in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: BMS-214662
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00005973

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

Phase 2

Terminated

Conditions: Cardiac Toxicity
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-06-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00019864

Locations: 🇺🇸
Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States

and more 1 locations

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Squamous Cell Carcinoma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage III Verrucous Carcinoma of the Larynx
Stage III Verrucous Carcinoma of the Oral Cavity
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx

Interventions: Drug: erlotinib hydrochloride
Drug: docetaxel
Radiation: radiation therapy
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00049283

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00045227

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: fenretinide

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00009971

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Phase 2

Completed

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00031915

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 7 locations

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

Phase 2

Terminated

Conditions: Adult Primary Cholangiocellular Carcinoma
Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Localized Extrahepatic Bile Duct Cancer
Localized Gallbladder Cancer
Localized Resectable Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: ixabepilone
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00023946

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: AIDS-related Diffuse Large Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma

Interventions: Biological: rituximab
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Drug: cyclophosphamide
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 106

Registration Number: NCT00049036

Locations: 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States

Home Terms & Conditions Privacy Policy